Trial Profile

Mesenchymal Stem Cells Under Basiliximab/Low Dose RATG to Induce Renal Transplant Tolerance.

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 18 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Remestemcel-L (Primary) ; Antithymocyte globulin; Basiliximab; Ciclosporin; Methylprednisolone; Mycophenolate mofetil
Indications Renal transplant rejection
Focus Therapeutic Use

Most Recent Events

09 Apr 2015 Biomarkers information updated
18 Jul 2013 Status changed from recruiting to discontinued as reported by European Clinical Trials Database.
04 May 2013 New source identified and integrated (European Clinical Trials Database: EudraCT2009-012350-20).

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com